The foremost gathering of CEOs of international and local pharmaceutical producers, distributors and retailers

11 - 12 November 2020

Corinthia Saint-Petersburg Hotel

Speaker confirmations in 2019

Elizabeth is currently the Real World Evidence generation Leader for China and Emerging Markets at Sanofi, Paris France.

Elizabeth is a Rheumatologist and Epidemiologist, with 18 years of experience in Real World Evidence and Market Access, spanning across research, consulting and Pharma.
Elizabeth has worked with regulators, payers, health care providers, and patients, to support decision-making through state of the art evidence, and more recently is part of the digital transformation, leveraging the most state of the art digital tools and ways of working to raise the level of innovation in evidence generation to improve patient outcomes.
Elizabeth is a Rheumatologist and an Epidemiologist, with an MPH from Harvard University.

Graduated from the Geography Department of Kazan Federal University. Received an MBA at the Management School of Lancaster University (UK). Has over 20 years of experience in senior managerial positions in the pharmaceutical industry.

In 2011 won the “Manager of the Year” as per Platinum Ounce award, a prominent professional award in the Russian pharmaceutical field. In 2015, became the Head of the Eurasia business unit — encompassing Russia, the CIS states, Georgia and the Ukraine — in a pharmaceutical company Bosnalijek (Bosnia and Herzegovina), one of the largest pharmaceutical manufacturers in the Balkan States and Eastern Europe. Recently, the business unit led by Valentina has increased its influence by entering the markets of Kazakhstan, Belarus and Azerbaijan.

In 2017, Bosnalijek, with its production sites in Sarajevo, became one of the first companies that had its application approved by the Russian Ministry of Industry and Trade and received a GMP certificate. The Russian market is vital to Bosnalijek’s future; it is the second year in a row that Bosnalijek sales continue to grow at a double-digit rate, which is significantly faster than the market. Bosnalijek best sellers are LYSOBACT and ENTEROFURYL, ranking among Top 3 in their categories.

Dr. Mikhail Samsonov is currently Head of Development, Medical and Regulatory at  R-Pharm managing all activities across several therapeutic areas (cardiology, oncology, infectious and autoimmune disease)  in fast growing R&D company. He is a member of several Joint Steering Committees with Merck, Eli Lilly, UCB, Theravance, Quintiles etc dedicated to technology transfer, development and commercialisation of innovative medicines, biosimilars and generics .

Prior R-Pharm he was Chief Scientific Officer at Novartis Russia & CIS overseeing all R&D activities for Novartis in one of key complex emerging markets and  member of Board of Directors Association of Clinical Trials Organizations in Russia in 2009-2011.

Dr Samsonov was Executive Director Regional Clinical Operations at Bristol-Myers Squibb Company overseeing EMEA and Asia Pacific regions including such emerging markets as China, India and Eastern Europe during last three years in BMS.  With over 14 years of experience at BMS in variety of roles in medical affairs and clinical operations, Dr Samsonov has dedicated much of his career to building capabilities in fast-growing clinical research markets , continuous productivity improvement in well established R&D markets and developing  10 new molecules in several areas ( antibiotics, autoimmune, CNS, CVS, oncology, virology). He was based at several BMS offices in the US, UK, Russia and Belgium.

Dr. Samsonov’s education includes MD from Moscow Medical University, National Cardiology Centre (Moscow) training  in Clinical Cardiology,  Ph.D. in Cardiology & Immunology from National Cardiology Centre, BA from Open University, London and several  business courses at INSEAD and OWEN business school.

He is an active speaker and panel expert at Columbia Business School, NY and various international conferences DIA, BIO USA, industry and investor meetings  on development  strategies, operational models, vendor management  in established and  emerging markets.  

In 1988 graduated from the Chelyabinsk State Medical Institute with a specialization in «General Medicine».
In 1998 completed postgraduate studies and defended a thesis on «anesthesiology-resuscitation» and «oncology» in the P.A. Herzen Moscow Oncology Research Institute.
Worked as a practitioner in various medical institutions of the RF, held senior positions in the Ministry of Health of the RF, in the Ministry of Health of Moscow Region and in leading pharmaceutical companies: MEDSI Group of Companies, Pharmeco LLC, Biotec LLC.
Since April 2018 has taken up the position of CEO of PJSC «Pharmacy Chain 36.6»
In 2002 and 2006 the Ministry of Health of Moscow Region gave Mr. Nesterenko a commendation for his diligent work.

Vice-President and Executive Director for Biomedical Technologies Cluster of Skolkovo Foundation. Natalia is responsible for developing innovative ecosystem and bringing innovative solutions to Healthcare, Pharmaceutical industry and Agro-tech.
Prior to joining Skolkovo in December, 2018 Natalia committed over twenty years to the pharmaceutical industry, holding top-managerial positions within leading pharmaceutical companies. Natalia started her career as a Medical Director at Bayer AG and later continued as a Regional Head for Ethical Products of Bayer HealthCare in Russia and CIS countries. In the following years Natalia held positions of Regional Business Head for Merck KGaA Oncology business in Russia and CIS countries, Chief Strategy Officer within the largest Russian pharmaceutical company Pharmstandard, General Manager in the Russian branch of the major world CRO Quintiles.
During that time Natalia has driven implementation of strategic innovations and best practices in all business functions across organization with special focus on pipeline development, precision medicine, multi-channel and patient-oriented solutions, while generating strong basis for companies’ substantial growth and leading position in the selected strategic markets. Elaborating her extensive experience, Natalia effectively led business transfer under several global M&As at country level, adopting cross-cultural approach for new company.
Natalia graduated from Moscow State Medical University and continued her professional education at Columbia University, School of Physicians & Surgeons, NYC, USA. Natalia holds scientific degree in NeuroScience and MBA degree from the American Institute of Business and Administration.

Yana Korzun, Senior Digital Manager Consumer Health Bayer. Joined the Media & Digital team as HCP Digital Manager in 2017. Leading the digital marketing strategy since 2019 in DTC & HCP promotion.

Yana has graduated the Moscow State University of Printing Arts of Ivan Fedorov, section of Journalism, upgraded her skills in “Advertisement and PR” in the University of Joongbu in South Korea

Yana has 7 years of experience in development and support of Digital Projects in large international pharmaceutical companies and FMCG-market.
She was responsible for PR & Digital in PRT (Edelman Affiliate).Yana was leading the development of communicational campaigns for the consumer and the professional sphere.

Master of science in physics (1995, Russian People Friendship University, experimental physics, computer aided modeling)
22+ years of experience in Information Technologies.
Was managing teams in marketing, sales, business development
for such companies as Optima, Microsoft, Algorithm
Last 5 years was Country manager for Software AG Russia&CIS.

Evgeniy Smirnov, Commercial Director of Navicon, was born on 4th of May 1978 in Yaroslavskaya oblast, Russia. In IT Consulting and Business Development for more than 15 years.

PhD of Yaroslavl State University and MBA of State University of Management. He worked for such companies as Sputnik Labs, BrightConsult, INTALEV, In IT Consulting and Business Development for more than 15 years. Since 2011 he has been working for Navicon Group of Companies as a Deputy General Director and a Commercial Director. He works to promote solutions and consulting services of Navicon.

Took part in dozens of projects (ERP, CRM, Budgeting systems, BI and DWH, and other business applications) for pharmaceutical and FMCG companies, finance and automobile industries. Realized complex automation project for one of the most hi-tech pharmaceutical manufacturers in Russia – “R-Pharm”. During the project more than 70 subsidiaries both in Russia and Kazakhstan got solutions to automate field force’s work and business processes based on Navicon Pharma CRM, and ERP solutions based on Microsoft Dynamics AX as well as data storage and BI based on Microsoft technologies. More than 700 employees of “R-Pharm” got fully automated workplaces.

Also took part in implementation of CRM and ERP solutions for 600 users in 20 cities of Russian Federation based on Oracle technologies in the Russia’s biggest travel agency as a head of the project and launch of the first online tour booking solution in Russia.

Victoria Andosova is a founder and CEO of Pharmhub. The company provides digital assets management solutions for pharmaceutical industry. She has worked for 18 years in the pharmaceutical retail industry as an operator and investor. In the recent past Victoria Andosova held position of Executive director of state-owned pharmaceutical fund “Moskovskaya apteka”, has founded and operated pharmacy retail chain located in Moscow region.
Victoria Andosova earned a Master’s degree in International Law from Moscow State University of International Relationships and a Master of Business Administration from the Cass Business School University of London.

Sergey focuses on mergers and acquisitions and capital raising advisory in Russia. Sergey has been managing numerous M&A engagements in various industries, including pharmaceuticals, FMCG, banking, packaging, metals and mining, oil & gas and others.

Before BIC Securities Sergey worked at KMPG Corporate Finance (Moscow office) for more than 3 years, where he was involved in M&A and fund raising projects.

Sergey graduated from Finance University under the Government of the Russian Federation.